Interferon therapy of multiple sclerosis;Interferontherapie der multiplen sklerose: Synopsis der verschiedenen applikationsformen

Nervenarzt

Volumn 75, Issue 12, 2004, Pages 1226-1229

  Jarius, S ^a   Hohlfeld, R ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Immunomodulatory therapy; Interferon ; Multiple sclerosis

Indexed keywords

BETA INTERFERON;

DRUG EFFICACY; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; REVIEW;

CLINICAL TRIALS; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PHYSICIAN'S PRACTICE PATTERNS; TREATMENT OUTCOME;

EID: 12444323088     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-004-1834-0     Document Type: Review

References (19)

1. Goodin DS, Frohman EM, Garmany GP Jr et al. (2002) Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS council for clinical practice guidelines. Neurology 58:169-178
2. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) (1999) Immunmodulatorische Stufentherapie der multiplen Sklerose. Nervenarzt 70:371-386
3. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) (2001) Immunmodulatorische Stufentherapie der multiplen Sklerose - 1. Ergänzung Dezember 2000. Nervenarzt 72:150-157
4. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) (2002) Immunmodulatorische Stufentherapie der Multiplen Sklerose - Neue Aspekte und praktische Umsetzung. Nervenarzt 73:556-563
5. Hartung HP, Schellekens H, Munschauer FE (2004) Neutralizing antibodies to interferon β in patients with multiple sclerosis. Scientific background and clinical implications. J Neurol 251 [Suppl 2]:iil-ill, ii1-42
6. Pachner D (2003) Anti-IFNβ antibodies in IFNβ-treated MS patients. Neurology 61 [Suppl 5]:S1-S39
7. Goodin D (2003) A comparison of the biological response and tolerability between the two high-dose, high-frequency β interferons in Healthy Volunteers. J Neurol 250 [Suppl 2]:306
8. Baum K, Hunter S (2004) Comparative study for two high-dose interferons in MS: comfort. J Neurol 251 [Suppl 3]:471
9. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498-1504
10. IFNB Multiple Sclerosis Study Group (1995) Interferon β-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45:1277-1285
11. Jacobs LD, Cookfair DL, Rudick RA et al. (1996) Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285-294
12. Buttmann M, Goebeler M, Rieckmann P (2004) Local pain during REBIF injection is not due to acidic pH. J Neurol Neurosurg Psychiatry 75:1078
13. Panitch H, Goodin DS, Francis G et al. (2002) Randomized, comparative study of interferon β-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 59:1496-1506
14. Durelli L, Verdun E, Barbero P et al. (2002) Every-other-day interferon β-1b versus once-weekly interferon β-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359:1453-1460
15. Phillips JT, Rice G, Frohman E et al. (2004) A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. Clin Ther 26:511-521
16. Hohlfeld R (1999) Immuntherapie der Multiplen Sklerose: Konsens und Kontroversen. Nervenarzt 70:297
17. Walther EU, Hohlfeld R (1999) Multiple sclerosis: side effects of interferon β therapy and their management. Neurology 53:1622-1627
18. Hohlfeld R (2001) Interferontherapie der Multiplen Sklerose. Eine Frage der richtigen Dosis? Nervenarzt 72:67-68
19. Jarius S, Hohlfeld R, Voltz R (2003) Diagnose und Therapie der Multiple Sklerose. Update 2003. MMW Fortschr Med 145 [Suppl 2]:88-95